Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
The wife of country music star Jelly Roll recently shared that she began using tirzepatide, an antidiabetic medication that was granted FDA approval to treat weight loss. But despite just taking a ...
NHS England has asked NICE to consider approving a slow phased rollout of tirzepatide (Mounjaro) for weight loss in primary care to avoid overwhelming GPs. It follows draft recommendations from NICE ...
NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes. In the SURMOUNT-4 trial ...
NHS leaders are considering a phased rollout of the obesity injection tirzepatide (Mounjaro, Eli Lilly) because of potentially high demand. The National Institute for Health and Care Excellence (NICE) ...
Eli Lilly’s blockbuster GLP-1 drug tirzepatide is finally back on track in the US after two years of intermittent shortages driven by high demand, the … ...
Tirzepatide, the active ingredient in the diabetes and obesity medications, was declared in shortage in December 2022. The shortage has been attributed to increased demand as interest in GLP-1 ...
Eli Lilly’s (NYSE:LLY) blockbuster GLP-1 medication, tirzepatide, is no longer in shortage in the U.S., the U.S. Food and Drug Administration (FDA) said on Wednesday. Tirzepatide, currently ...
Mounjaro has been on the FDA's shortage list since late 2022, while Zepbound was added to the list in April this year. The drugmaker had begun selling vials of the lowest starter dose of Zepbound in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback